In subjects with type 2 diabetes, exenatide use was associated with higher flow-mediated dilation than glimepiride.
In plain wordsIn people with type 2 diabetes, exenatide was linked to greater artery dilation than glimepiride.
- Peptide
- Exenatide (exendin-4)
- Outcome
- IncreaseFlow-mediated dilation
- Study
n: not reported in source
- Comparator
- Glimepiride
- Outcome group
- Vascular function · Cardiovascular
- Studied dose
- Dose not stated · 16 weeksAs given in this study (human).
Measurements
- Flow-mediated dilation
- 9.1 unit not stated
- exenatide group, mean (± 3.6 as written)
- Flow-mediated dilation
- 5.6 unit not stated
- glimepiride group, mean (± 1.0 as written)
Source sentences
At the end of the study FMD was significantly higher in subjects who assumed exenatide compared with glimepiride (9.1 ± 3.6 vs. 5.6 ± 1.0, p = 0.01).
2 context sentences(design, population, supporting numbers)
The aim of our observational study was to evaluate whether exenatide would improve brachial artery function evaluated by the flow mediated dilation (FMD) technique, compared with glimepiride, in subjects with type 2 diabetes.
FMD time course was assessed by ultrasound, after 5 min forearm ischaemia, at baseline and after 16-week treatment.